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Abstract
An international committee set up through the IAP for Health 
met to develop an action plan for dementia. Comprehensive 
international and national initiatives should move forward 
with calls for action that include increased public awareness 
regarding brain health and dementia, support for a broad range 
of dementia research objectives, and investment in national 
health care systems to ensure timely competent person-centred 
care for individuals with dementia. The elements of such 
action plans should include: 1) Development of national plans 
including assessment of relevant lifecourse risk and protective 
factors; 2) Increased investments in national research programs 
on dementia with approximately 1% of the national annual cost 
of the disease invested; 3) Allocating funds to support a broad 
range of biomedical, clinical, and health service and systems 
research; 4) Institution of risk reduction strategies; 5) Building 
the required trained workforce (health care workers, teachers, 
and others) to deal with the dementia crisis; 6) Ensuring that it 
is possible to live well with dementia; and 7) Ensuring that all 
have access to prevention programs, care, and supportive living 
environments.
Key words: Risk reduction strategies, risk factors, life course, public 
awareness, national plans
Introduction
This statement has been prepared by an international committee set up through the InterAcademy Partnership for Health (IAP-H), which is a component 
of the InterAcademy Partnership (IAP). The InterAcademy 
Partnership (IAP) was launched in 2016, and currently has 
a membership of 135 academies of science, medicine and 
engineering from around the world. These include both national 
academies/institutions as well as regional/global groupings of 
scientists. This statement is modified from a position paper that 
was initially commissioned by the Canadian Academy of Health 
Sciences, and written, approved and submitted by the Research 
Executive Committee (REC) of the Canadian Consortium on 
Neurodegeneration in Aging (CCNA). Members of the Research 
Executive Committee of the CCNA and the International IAP 
committee on Dementia also appear at the end of the statement.
The proportion of the world’s population that is 65 
years of age or greater has grown over the last number 
of decades, and this trend will continue. Advancing 
age is the greatest known risk factor for dementia (1, 2). 
If there is no change in age-standardized prevalence, 
societal aging is predicted to nearly triple the number 
of individuals living with dementia worldwide by 
2050 (3, 4). It is estimated by that year the number of 
individuals with dementia will rise from 47.5 million 
people to an estimated 135.5 million with most of this 
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increase occurring among people living in low- and 
middle income countries (2). Aside from the personal 
cost of dementia, these rising numbers will be associated 
with an economic burden. The 2015 global estimated cost 
of dementia was US $818 billion and is expected to be a 
trillion dollars by 2018 (5).
The World Health Organization (WHO) now 
recognizes dementia as a public health priority (6, 7). 
To respond to this challenge, a global series of actions 
initiated during the UK G8-Presidency in 2013 were 
undertaken by bodies such as the Organisation 
for Economic Co-operation and Development (OECD; 
8), Alzheimer’s Disease International (ADI) and by 
the World Dementia Council (WDC; 9). 
Dementia Overview
Dementia is an acquired, persisting and typically 
progressive decline in cognitive abilities, affecting 
learning and memory, language, and/or reasoning 
that is severe enough to interfere with independence 
in everyday activities. It becomes more common 
with increasing age during adulthood. Besides 
cognitive impairment, dementia is often associated 
with debilitating neuropsychiatric symptoms, such 
as agitation, psychosis, sleep disturbance, depression, 
anxiety and apathy (10). Dementia can arise from 
numerous conditions acting alone or in combination (11, 
12). For many, it is due to a neurodegenerative 
process, an umbrella term for a number of debilitating 
conditions that result in the progressive degeneration 
and/or death of neurons (5). Alzheimer disease is the 
most common neurodegenerative cause of dementia 
and is currently incurable. A mixture of brain 
diseases often underlies dementia, with many people 
showing changes consistent with both Alzheimer and 
cerebrovascular disease (13, 14). Dementia is usually a 
slowly progressive illness where the diagnosis is made 
after the process has been present for years (15).
Risk factors and conditions (such as smoking, or 
diabetes) commonly associated with vascular conditions 
(stroke, heart disease) are also known to be associated 
with dementia (16, 17). Frailty itself is a considerable risk 
factor for dementia (18). Parkinson’s disease is closely 
associated with the development of dementia (19). The 
majority of older individuals with dementia have mixed 
pathology in their brain (11, 12, 20, 21).
While young onset (under 60 years) dementia is 
seen infrequently in many countries, this may not be 
the case in countries with high HIV prevalence. The 
HIV epidemic is concentrated in younger people 
of low-income countries, particularly in Sub-Saharan 
Africa, where young people may subsequently bear a 
disproportionately greater burden of dementia (22).
Women are at both greater risk of developing dementia 
and then living longer with the condition after its onset 
(23). Women also provide most of the informal (unpaid) 
care for people living with dementia.
While there are currently no cures for the 
neurodegenerative conditions that lead to dementia, 
emerging research suggests that some life-style 
factors (e.g., engaging in physical activity, managing 
blood pressure, selected forms of cognitive training) 
may have the potential to delay, if not prevent, its onset 
(24-27). Population studies have suggested additional 
associated risk and protective factors, which require 
research to evaluate their potential as primary prevention 
intervention targets (28, 29). The progress to date in 
developing effective pharmacological treatment options 
has been disappointing (30-32), underscoring the need 
to understand better what contributes to the dementia 
syndrome in different generational cohorts as well as in 
different populations (33).
A key area for research and support is the 
development and dissemination of improvements for the 
care provided to people living with dementia including 
compassionate and appropriate end-of-life care (34-37). 
Greater acceptance and inclusion of people living with 
dementia within communities is increasingly seen as an 
important factor in improving their quality of life and 
minimizing disability (7, 38). The needs of patients and 
their families change along the course of dementing 
illnesses and it is necessary to gear support and therapy 
for the different stages of the disease.
A Call to Action 
Because of these issues, developing a comprehensive 
strategy internationally to address the challenges 
of dementia will require wide consultation followed 
by the long-term implementation of a comprehensive, 
integrated and responsive series of actions. Most 
initiatives will be nationally based, but additional 
international collaborations to address dementia will also 
be advantageous. The nationally-based initiatives will 
generally share similar high-level goals and principles to 
address this global health problem. We call for countries 
within regions that have resources, to establish a network 
that can support other countries similar to them in their 
approach to dementia. The goals and principles of a call 
to action would include addressing the following broad 
areas: (a) increasing public awareness - educating the 
general population about dementia, how to maintain 
brain health, and on the importance of addressing this 
health challenge, accepting people with dementia as they 
are, and accommodating to their remaining abilities; (b) 
supporting fundamental research to find and implement 
effective approaches (both pharmacological and non-
pharmacological) to delay, prevent, slow down, treat, 
ameliorate, and eventually cure the common causes of 
dementia; (c) investing in national health care systems 
– this would entail both training a sufficient number 
and mix of providers as well as building the necessary 
infrastructure to ensure timely, competent person-
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centered care is available to those living with dementia 
and their caregivers through all stages of the illness.
Our Call to Action is one which aims at developing an 
evidence-based and a public health orientated approach. 
Ultimately, this should include a clear assessment for 
each population of the potential for primary prevention 
(upstream prevention), secondary prevention (early 
detection followed by effective treatment, considered 
to be likely more effective at that stage than later) and 
tertiary prevention (mitigation of dementia and its 
ramifications through various therapies and end-of-life 
care for those with dementia).
Elements of an Action Plan to Face the 
Challenge of Dementia
An action plan to face the challenge of dementia in its 
global context must include a concerted and coordinated 
series of actions from policies, to research, to care, to 
social  inclusion. Here are seven key elements of such an 
action plan.
National dementia plans must be established
National plans to combat dementia have been initiated 
in 29 countries/states since 2005. There is a global plan on 
dementia being developed by the WHO (6, 7) and the first 
regional plan on dementia in the Americas, published 
by the Pan American Health Organization (PAHO) in 
October 2015 (See the website of ADI https://www. 
alz.co.uk/dementia-plans/ for a list of national plans 
currently underway as well as countries currently lacking 
national plans). Canada is the only G7 country without a 
national dementia plan (39).
Each country should develop a national plan 
coherent with its health care goals which could 
coordinate activities, harmonize where appropriate with 
international efforts, promote the sharing of successful 
local initiatives, address identified gaps, ensure efficient 
use of resources, and mobilize further investment in 
all aspects of dementia including care and research. A 
national plan would acknowledge dementia as a public 
health priority and heighten awareness of this daunting 
health challenge.
As a first step towards such plans, we propose that 
a national dementia status report should be carried out 
in as many countries with resources as possible. Such 
a status report for each region would be wide-ranging, 
including burden of all dementia types, comorbid 
disorders, risk factors, therapeutic approaches and care 
systems.
More research is necessary to establish the strength 
and interaction of lifecourse risk and protective factors 
relevant to dementia. Nevertheless, assessment of the 
“exposome”, potential risk and protective factors for each 
population, would be an important part of this report 
(40, 41). These should establish, for key lifestages, the 
balance in those populations of positive and negative 
features for brain health (42, 43). This would encompass 
a broad range of environmental factors such as maternal 
health, early life health, infections, education, vaccination, 
as well as adverse exposures such as poor housing, 
smoking, poor diet, and exposure to noxious substances.
A 5-year follow-up report should be planned to 
document the impact of national policies (public 
awareness, risk factors, care systems, etc.) and the 
creation of a national dementia strategy.
Increase investment in national research 
programs on dementia
The investment in medical research varies widely 
across countries. In 2016 the American investment in 
dementia research was US $936 million, which translates 
to US$2.93 per capita (23). In contrast, the Canadian 
investment in research on dementia was smaller (less 
than a quarter per capita of what is invested in the USA; 
44). Overall, developed countries do not adequately 
invest in dementia research when compared to 
the funding of research on other conditions such as 
cancer and heart disease even though the cost of 
caring for persons with dementia is estimated to be 
greater than that for dealing with either of the other 
two conditions (45, 46). It has been stated that a 
goal of 1% of the national annual cost of dementia 
should be steered into dementia research programs 
(Dementia in Canada: A National Strategy for 
Dementia-friendly Communities, Report from 
Canadian Senate, 2016; 6). This additional investment 
in each country will have to be thoughtfully allocated 
and managed. Broad coordination within each country 
should be organized for best use of research funds. 
Governance and prioritization of dispersal of these 
funds must also involve individuals living with 
dementia and their caregivers, the research community, 
and practitioners.
This investment must span all aspects of 
dementia research
Allocated research funds should support a 
broad range of activity from biomedical 
investigation to inquiries dealing with clinical 
aspects, health systems and services research. 
There must be fundamental research to unveil the 
mechanisms involved in the onset of 
neurodegenerative diseases and hopefully pave 
the way to a specific and effective pharmacological 
treatment. In addition, research to gain better insight 
into understanding the social cultural and environmental 
factors that affect the health of populations is essential. 
Investments should target national research capacity, 
supporting knowledge transfer, addressing the needs of 
unique populations (for example, indigenous people and 
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those living in rural and remote communities; 47-49), 
investigating sex and gender differences in dementing 
conditions, and embracing ethical and social dimensions 
(50, 51).
There is now considerable potential for earlier 
diagnosis of various forms of dementia using clinical, 
imaging, and biomarker support (52). The advantages 
and potential of early diagnosis is a critical focus of 
research in Western countries (53-57). Attention must 
now be paid to delineating the optimal approaches to 
early diagnosis and establishing the risks and benefits of 
translating this knowledge into health care policy.
The neuropsychiatric (behavioral and psychological) 
symptoms of dementia need more attention given their 
strong impact on quality of life, caregiver burden and 
rate of institutionalization (10, 58, 59 60). Future research 
into the prevalence, etiology and therapy (including 
randomized controlled trials) of neuropsychiatric 
symptoms of dementia is needed. 
There must be research investment into understanding 
what combinations of modifiable lifestyle factors 
across the lifecourse increase and decrease the risk, of 
developing dementia with aging (26, 61). This is not 
a one-size-fits-all syndrome across the globe. The 
combinations of relevant risk factors may vary in 
different cultures and communities. The most effective 
preventative and public health strategy for dementia 
will only emerge when the fullest understanding of these 
factors is achieved.
Specific attention should be devoted to the support 
of social research aimed at identifying the actual needs 
of subjects with dementia and their caregivers (62-64). 
The general purpose of such investigations would be the 
planning of multifaceted interventions encompassing 
environmental, psychological, medical and social 
support.
Risk reduction strategies should be instituted
While there is still a considerable amount to learn 
about the full interplay of risks, governments must 
support national risk reduction and empowerment 
strategies for the public and support the efforts of 
health professionals to promote healthy brain aging. 
Current evidence can be used to empower the public 
and health professionals to act in ways that will reduce 
the risks of all dementia types developing, postponing 
the appearance of their clinical manifestations, and 
optimizing everyday functioning in meaningful social 
activities and roles. The focus of such risk reduction 
would include treatment and prevention of vascular risk 
factors – hypertension, obesity, diabetes, smoking, and 
high-calorie diets, and treatment of HIV to prevent HIV-
related dementia. It would also include risk reduction 
to address sleep problems, illiteracy, head trauma, 
malnutrition, and physical inactivity in addition to other 
region-specific risk factors (5).
Risk reduction at the individual level must be 
supplemented by evidence-based structural and 
legislative alterations that support these reductions. 
Smoking legislation, strategies for excessive alcohol 
risk reduction, reduction of dietary salt, legislation to 
reduce head injuries are only a few of the risk reduction 
strategies that can be undertaken by governments to 
affect the occurrence of dementia in the population. Such 
governmental interventions will lead to less inequality 
because they benefit the disadvantaged as well. The  
WHO Global Noncommunicable  Diseases Action Plan 
2013-2020 focuses on many of these elements (6).
The required workforce must be planned and 
trained
Workforce requirements to deal with the increasing 
number of persons with dementia must be determined 
and steps taken to ensure the required workforce is both 
trained and supported in their activities. A well trained 
and supported workforce of the right mix and number 
to deal with the needs of this emerging population is 
required. In each country, a national workforce plan 
will have to be created and implemented with the active 
involvement of local and regional authorities.
The full breadth of necessary trainees will only 
emerge after appropriate evidence-based strategies 
for risk reduction emerge. The workforce trained will 
initially be focused on the elderly, and the health care 
sector, but addressing modifiable risks (for example, 
limited education, early childhood nutrition) implies an 
investment in teachers, nutritionists, and a host of other 
professionals in the future.
We must ensure that it is possible to live well 
with dementia
When a diagnosis of dementia is made, an individual 
should not be constrained to abandon her/his 
social role and participation. Creating the conditions 
within a country where one can live well with 
dementia includes ensuring that the public is aware 
of dementia in all its complexity, that there are 
accommodations in the environment (including 
work) to compensate for changing abilities, that 
there is adequate protection against abuses of all 
kinds against individuals living with dementia, and 
legal that rights are not automatically withdrawn 
from people living with dementia. Cooperation 
between academies and local administration should be 
encouraged so that all the needs of persons living 
with dementia and of their caregivers can be 
assessed and met.
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Access to prevention and care should be made 
available to all
To the extent possible, access to preventive programs, 
systems of care, and supportive living 
environments should be made available to all citizens 
with, or at risk of, dementia (49, 65-67)
The Future of the Dementia Challenge
Dementia will be part of the global landscapes for 
many decades, reaching levels that are least twice the 
current 2016 values. Indeed, even if research could 
provide the means of eradicating brain diseases causing 
dementia tomorrow, numerous individuals would 
already be on the trajectory to dementia. Brain 
diseases causing dementia are now known to start 
many decades before any clinical signs. For these 
reasons, a total solution will not be available for 
some time to come. This is why the member 
Academies of IAP for Health are focusing attention on 
the necessity of engaging in an action plan for dementia 
which is balanced and designed to address all 
aspects of the challenge, especially the wellness 
of those living with dementia and their caregivers.  
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